As of 2024-12-14, the EV/EBITDA ratio of EyePoint Pharmaceuticals Inc (EYPT) is -3.98. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EYPT's latest enterprise value is 460.88 mil USD. EYPT's TTM EBITDA according to its financial statements is -115.78 mil USD. Dividing these 2 quantities gives us the above EYPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 10.0x | 8.6x |
| Forward P/E multiples | 13.1x - 19.1x | 16.2x |
| Fair Price | (21.03) - (15.76) | (19.95) |
| Upside | -364.9% - -298.5% | -351.3% |
| Date | EV/EBITDA |
| 2024-12-12 | -3.91 |
| 2024-12-11 | -4.16 |
| 2024-12-10 | -4.29 |
| 2024-12-09 | -4.52 |
| 2024-12-06 | -4.43 |
| 2024-12-05 | -4.11 |
| 2024-12-04 | -4.30 |
| 2024-12-03 | -4.23 |
| 2024-12-02 | -4.46 |
| 2024-11-29 | -4.52 |
| 2024-11-27 | -4.63 |
| 2024-11-26 | -4.60 |
| 2024-11-25 | -4.74 |
| 2024-11-22 | -4.57 |
| 2024-11-21 | -4.22 |
| 2024-11-20 | -4.58 |
| 2024-11-19 | -4.73 |
| 2024-11-18 | -4.36 |
| 2024-11-15 | -4.70 |
| 2024-11-14 | -5.48 |
| 2024-11-13 | -5.64 |
| 2024-11-12 | -5.85 |
| 2024-11-11 | -6.37 |
| 2024-11-08 | -6.15 |
| 2024-11-07 | -6.13 |
| 2024-11-06 | -6.42 |
| 2024-11-05 | -6.14 |
| 2024-11-04 | -6.19 |
| 2024-11-01 | -6.40 |
| 2024-10-31 | -6.23 |
| 2024-10-30 | -6.05 |
| 2024-10-29 | -6.10 |
| 2024-10-28 | -6.44 |
| 2024-10-25 | -4.90 |
| 2024-10-24 | -4.93 |
| 2024-10-23 | -5.17 |
| 2024-10-22 | -5.63 |
| 2024-10-21 | -5.60 |
| 2024-10-18 | -5.81 |
| 2024-10-17 | -5.87 |
| 2024-10-16 | -5.95 |
| 2024-10-15 | -5.12 |
| 2024-10-14 | -5.29 |
| 2024-10-11 | -4.50 |
| 2024-10-10 | -4.16 |
| 2024-10-09 | -4.25 |
| 2024-10-08 | -4.30 |
| 2024-10-07 | -4.43 |
| 2024-10-04 | -4.39 |
| 2024-10-03 | -4.23 |